化疗致肠黏膜炎的病理机制及药物干预策略研究进展  

Advancement on pathogenesis of chemotherapy induced intestinal mucositis and its drug intervention:a review

作　　者：郭锦瑞[1] 詹臻[2] 康安[1,2] 王小龙[1] 

机构地区：[1]南京中医药大学药学院 [2]南京中医药大学中西医结合一级学科

出　　处：《中国临床药理学与治疗学》2014年第5期573-578,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：江苏高校优势学科建设工程资助项目;国家自然科学基金项目(81202983);南京中医药大学青年自然科学基金项目(11XZR09)

摘　　要：肠黏膜炎是化疗过程中的一种常见不良反应,具有发生率高、危害大的特点,严重影响肿瘤患者的治疗及生活质量。研究表明化疗致肠黏膜炎的病理生理学机制复杂,目前药物可干预的环节较多,但疗效尚不确切。本文综述了化疗致肠黏膜炎的病因及可能机制,并对缓减化疗毒副作用的药物及其干预环节进行了总结概况。以期为该疾病的合理治疗及相关药物的开发提供参考。Intestinal mucositis is a common adverse reaction during chemotherapy, which was with high incidence, toxic, serious impact on cancer treatment and quality of life. Studies show that the pathogenesis of intestinal mucositis induced by chemotherapy is complex, thus the current drug intervention strategies were more, but the curative effect is not exact. In this paper, we reviewed the etiology of intestinal mucosal inflammation induced by chemotherapyand its possible mechanism, and summarized the possible mitigation way to alleviate the chemotherapy induced side effects. From this paper, we could provide reference for the development of rational treatment of this disease and related drugs.

关 键 词：化疗 肠黏膜炎 治疗策略 

分 类 号：R574[医药卫生—消化系统]